ALK and non-small cell lung carcinoma: In a phase 1/2, single-arm, open-labelled study (AF-001JP) [58], 93.5% (43/46) of patients with ALK-rearranged NSCLC who had not received crizotinib previously achieved an objective response when receiving alectinib at the recommended dose (300 mg twice per day).